Evido Health enters a collaboration agreement with Roche to address the global health challenge of Steatotic Liver Disease (MASH, Met-ALD, ALD)

Copenhagen, Denmark, 2025-10-01.

‍

Evido Health announced today that they have entered a non-exclusive collaboration agreement with Roche to distribute their LiverPRO technology to physicians and patients through the navify Algorithm Suite from Roche.

‍

LiverPRO is a CE-certified medical software technology specifically designed for detecting liver fibrosis amongst people with certain risk factors. Liver fibrosis is a globally widespread but asymptomatic and often undiagnosed disease, potentially leading to severe and fatal complications if not prevented and reversed in time. Three out of four patients diagnosed with cirrhosis (end-stage liver disease) seek medical assistance when it is too late to intervene¹. This collaboration agreement will address this exact challenge by enabling access to affordable, efficient, and non-invasive testing during existing consultations with at-risk patients worldwide.

‍

The combination of LiverPRO and Roche’s upcoming but established liver care panel will create a unique offering of an end-to-end pathway based entirely on medically validated and certified blood-based biomarkers and algorithms. LiverPRO is bridging a gap in the market by enabling timely detection of liver fibrosis based on blood sample results from existing patient consultations. Not only does this benefit patients but also the healthcare systems at large. Better use of existing consultations and data is an essential strategy for detecting and stratifying patients at this scale, while also catering for the constrained resources and budgets that healthcare systems suffer from. Notably, as patients will be examined at the initial point of care, it could not only enable timely detection and treatment but also significantly reduce the referrals to and pressure on specialist departments. Instead, hepatologists can focus on preventing and reversing liver fibrosis among affected patients.

‍

"We are really pleased with today’s announcement and our collaboration with Roche. This is great news for especially physicians and patients, who will now have the chance to use our LiverPRO technology through the navify Algorithm Suite from Roche.” said Taus Holtug, CEO and Co-Founder of Evido. “Liver fibrosis is a global challenge that needs to be addressed. We are excited to help by ensuring better diagnosis and further distribute our LiverPRO technology with Roche.”

‍

¹ Fialla, A.D., de Muckadell, O. B. S., and Touborg Lassen, A. (2012). Incidence, etiology and mortality of cirrhosis: a population-based cohort study. Scandinavian Journal of Gastroenterology 47(6): pp. 702-709. PMID: 22428859. DOI: 10.3109/00365521.2012.661759

‍

About LiverPRO

‍

LiverPRO is a CE-certified medical software technology specifically designed for detecting liver fibrosis amongst people with risk factors. Based on machine learning, LiverPRO uses the results from standard blood tests to predict the level of scar tissue in the liver, i.e., liver fibrosis. The risk score derived from using LiverPRO is accompanied by a specific clinical recommendation to empower physicians with actionable recommendations to streamline the diagnosis and management of the patient.

‍

LiverPRO is an important piece of the puzzle to disrupt the current paradigm around Steatotic Liver Disease (MASH, Met-ALD, ALD) diagnostics, going from reactive to preventive care. LiverPRO is considered a highly innovative solution not only by its advanced technology but also its user-centric approach and scalability, ensuring successful implementation and value creation across healthcare systems.

‍

About Evido Health

‍

Evido Health is a health tech company based in Denmark since founded in 2021, originating from and building on more than a decade of clinical research within the field of liver disease diagnostics. Having seen the effect of late detection and the related complications of cirrhosis first-hand, Evido strives to improve the lives of patients by giving them the chance to change course before it is too late. On a mission to ensure timely detection of millions of undiagnosed patients, Evido offers a highly innovative solution that leverages existing healthcare data better. Evido is working with leading key opinion leaders and companies in the field that share the same ambitions.

‍

Links for further information

‍

For regular updates, please visit and follow Evido Health on LinkedIn.

‍

Contacts for further information

‍

Taus Holtug, CEO and Co-Founder, Evido Health

Email: taus@evido.health

‍

Louise Jönsson, Brand and Communications Manager, Evido Health

Email: louise.jonsson@evido.health